Abstract 454P
Background
T-DXd is approved as 2L or later treatment for HER2-positive gastric cancer in several countries and is considered emetogenic. Nausea and vomiting affect significantly patient quality of life, leading to poor compliance with further treatment. Therefore, we sought to identify the optimal combination of antiemetic prophylaxis with T-DXd.
Methods
This study was a multicenter, randomized, open-label, non-comparative, Ph2 study to investigate optimal antiemetic prophylaxis for Japanese patients (pts) with gastric cancer treated with T-DXd. The pts were randomized to a doublet regimen (DxR, dexamethasone and palonosetron) or a triplet regimen (TxR, aprepitant in addition to doublet regimen) at a ratio of 1:1; stratified by gender, gastrectomy status, and study site. T-DXd admiration was started at 6.4 mg/kg and the antiemetic prophylaxis was administered from day 1 up to day 5. The primary endpoint was antiemetic complete response (CR, defined no emetic event and no rescue drug) rate to assess control emesis based on patient reported outcomes for 21 days. CR rate in acute phase (0-24hr) and delayed phase (2-21d) were evaluated as a secondary endpoint. With 29 pts per arm, the primary analysis considered a regimen promising if either arm had ≥18 CRs.
Results
A total of 58 pts were eligible for this analysis. Three pts were discontinued follow-up (2 pts in DxR, 1 pt in TxR). Both antiemetic CR rate for 21 days (overall) and CR rate in delayed phase were 41.4% (12/29) for DxR and 37.9% (11/29) for TxR. The antiemetic CR rate in acute phase was 86.2% (25/29) in both regimens. The median first emetic event occurred at 3 day in both regimens.
Conclusions
Both antiemetic prophylaxis regimens did not meet the prespecified antiemetic CR rate. This study, which used patient reported outcome to assess emetic events, has resulted in a higher rate of emetic events compare to monitoring by physicians reported in previous studies. Given the study design and small sample size, further research may help to fully characterize nausea and vomiting with T-DXd in gastric cancer pts.
Clinical trial identification
jRCTs031200336.
Editorial acknowledgement
Legal entity responsible for the study
Yokohama City University Hospital, Epidemiological and Clinical Research Information Network (ECRIN), and Daiichi Sankyo Co., Ltd.
Funding
Daiichi Sankyo Co., Ltd.
Disclosure
K. Oba: Financial Interests, Personal, Invited Speaker: Chugai, Daiichi Sankyo; Financial Interests, Personal, Other, IDMC member: Eisai, Ono pharmaceutical co, Janssen. K. Nishikawa: Financial Interests, Personal, Invited Speaker, Lecture fee: Bristol Myers Squibb, Daiichi Sankyo, EA Pharma, Eli Lilly, MSD, Ono, Taiho, Yakult. H. Maeda: Financial Interests, Personal, Invited Speaker: Tsumura Co; Financial Interests, Personal, Writing Engagement: Igaku-shoin; Non-Financial Interests, Personal, Other, journal editor: Annals of cancer research and therapy; Non-Financial Interests, Personal, Other, research advisory: Japanese foundation of multidisciplinary cancer treatment; Non-Financial Interests, Personal, Other, editorial board: Japanase society of human cells. A. Makiyama: Financial Interests, Personal, Invited Speaker: Eli Lilly, Taiho, Ono, Daiichi Sankyo, Bristol Myers Squibb. T. Oshima: Financial Interests, Personal, Invited Speaker: Taiho, Astellas; Financial Interests, Personal, Writing Engagement: Astellas; Financial Interests, Personal, Other, research grant: Taiho, Kyowa Kirin, Chugai, Nihon kayaku. A. Katayama: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo; Financial Interests, Personal, Stocks/Shares: Daiichi Sankyo. K. Shiosakai: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
270P - Germline BRCA1/2 pathogenic variants in Japanese patients with prostate cancer are predictive factors for androgen receptor-axis-targeted therapy or chemotherapy for castration-resistant prostate cancer
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract
271P - Prostate cancer with histone modifier UTX mutations can benefit from olaparib
Presenter: NOBUHITO MURAMOTO
Session: Poster Display
Resources:
Abstract
272P - Comparison between MRI-targeted and standard biopsy for prostate cancer detection: A systematic review and meta-analysis
Presenter: Andree Kurniawan
Session: Poster Display
Resources:
Abstract
273P - The diagnostic performance of cognitive MRI-targeted biopsy in biopsy-naïve patients undergoing systematic 14-region 18-core biopsy: Do the three areas affect the results?
Presenter: Yuka Toyama
Session: Poster Display
Resources:
Abstract
274P - Index tumor location influencing early biochemical recurrence after radical prostatectomy in patients with negative surgical margins
Presenter: Jun Akatsuka
Session: Poster Display
Resources:
Abstract
275P - Prognosis of metastatic castration-resistant prostate cancer in response to chemotherapy and PSMA expression in circulating tumor cells
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
276P - Prognostic significance of p53 mutation in metastatic hormone-sensitive prostate cancer
Presenter: Lakshmi Kamala
Session: Poster Display
Resources:
Abstract
277P - Vasohibin-1 expression as a biomarker of aggressive growth in prostate ductal adenocarcinoma
Presenter: Murad Salomov
Session: Poster Display
Resources:
Abstract
278P - Full-coverage radiotherapy for prostate cancer patients with oligometastases
Presenter: Bichun Xu
Session: Poster Display
Resources:
Abstract
279P - Hypofractionated radiotherapy protocol implementation and early outcomes for prostate cancer patients: A single institution retrospective review
Presenter: Thu Nguyen
Session: Poster Display
Resources:
Abstract